Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 May 1;87(6):1283-95.
doi: 10.1002/jnr.21949.

Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease

Payal N Gandhi  1 , Shu G Chen, Amy L Wilson-Delfosse
Affiliations
Review

Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease

Payal N Gandhi et al. J Neurosci Res. .

Abstract

Parkinson's disease (PD) is the most common neurodegenerative movement disorder, with a prevalence of more than 1% after the age of 65 years. Mutations in the gene encoding leucine-rich repeat kinase-2 (LRRK2) have recently been linked to autosomal dominant, late-onset PD that is clinically indistinguishable from typical, idiopathic disease. LRRK2 is a multidomain protein containing several protein interaction motifs as well as dual enzymatic domains of GTPase and protein kinase activities. Disease-associated mutations are found throughout the multidomain structure of the protein. LRRK2, however, is unique among the PD-causing genes, because a missense mutation, G2019S, is a frequent determinant of not only familial but also sporadic PD. Thus, LRRK2 has emerged as a promising therapeutic target for combating PD. In this Mini-Review, we look at the current state of knowledge regarding the domain structure, amino acid substitutions, and potential functional roles of LRRK2.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1. Schematic representation of the predicted LRRK2 domain structure
LRRK2 is composed of 13 LRRs, followed by the Roc, COR, and MAPKKK domains, as well as seven WD40 repeats at the C-terminus. Mutations that are considered definitively pathogenic are shown in red. Amino acid substitutions that can act as risk factors for disease and are putatively pathogenic are shown in green. Mutations that have been identified in PD patients but for which pathogenicity is uncertain are shown in blue. The amino acid residue numbers beneath each domain indicates the estimated domain boundaries. Predicted functions of each of the LRRK2 domains are listed. The GenBank accession number for human LRRK2 is AAV63975.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Aasly JO, Toft M, Fernandez-Mata I, Kachergus J, Hulihan M, White LR, Farrer M. Clinical features of LRRK2-associated Parkinson’s disease in central Norway. Ann Neurol. 2005;57(5):762–765. - PubMed
    1. Adams JR, van Netten H, Schulzer M, Mak E, McKenzie J, Strongosky A, Sossi V, Ruth TJ, Lee CS, Farrer M, Gasser T, Uitti RJ, Calne DB, Wszolek ZK, Stoessl AJ. PET in LRRK2 mutations: comparison to sporadic Parkinson’s disease and evidence for presymptomatic compensation. Brain. 2005;128(Pt 12):2777–2785. - PubMed
    1. Alegre-Abarrategui J, Ansorge O, Esiri M, Wade-Martins R. LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson’s disease. Neuropathol Appl Neurobiol. 2008;34(3):272–283. - PMC - PubMed
    1. Berg DSK, Leitner P, Zimprich A, Lichtner P, Belcredi P, Brussel T, Schulte C, Maass S, Nagele T. Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson’s disease*. Brain. 2005;128(Pt 12):3000–3011. - PubMed
    1. Bialecka M, Hui S, Klodowska-Duda G, Opala G, Tan EK, Drozdzik M. Analysis of LRRK 2 G 2019 S and I 2020 T mutations in Parkinson’s disease. Neurosci Lett. 2005;390(1):1–3. - PubMed

Publication types

MeSH terms

Substances